Drug Profile

ABL 301

Alternative Names: ABL-301; SAR-446159

Latest Information Update: 10 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ABL Bio
Class Antiparkinsonians; Bispecific antibodies
Mechanism of Action Alpha-synuclein inhibitors; IGF type 1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Parkinson's disease

Most Recent Events

21 Jun 2022 ABL Bio plans for IND enabling studies for Parkinson’s Disease in second half of 2022 (ABL Bio pipeline, June 2022)
21 Jun 2022 ABL 301 is still in preclinical phase for Parkinson’s Disease in South Korea (ABL Bio pipeline, June 2022)
28 Apr 2022 No recent reports of development identified for preclinical development in Parkinson's-disease in South Korea (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com